Appropriateness of virological monitoring with long-acting injectable cabotegravir and rilpivirine

被引：0
|
作者：
Ripamonti, Diego [1 ]
Borghetti, Alberto [2 ]
Zazzi, Maurizio [3 ]
机构：
[1] ASST Papa Giovanni XXIII, Infect Dis Unit, Bergamo, Italy
[2] Azienda Osped Univ Pisana, Infect Dis Clin, Pisa, Italy
[3] Univ Siena, Dept Med Biotechnol, Siena, Italy
来源：
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2024年 / 79卷 / 10期
关键词：
HIV;
D O I：
10.1093/jac/dkae257
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：2720 / 2724
页数：5
相关论文
共 50 条
  • [1] Virological Failure After Switch to Long-Acting Cabotegravir and Rilpivirine Injectable Therapy: An In-depth Analysis
    van Welzen, Berend J.
    Van Lelyveld, Steven F. L.
    Ter Beest, Gerjanne
    Gisolf, Jet H.
    Geerlings, Suzanne E.
    Prins, Jan M.
    Van Twillert, Gitte
    Van Nieuwkoop, Cees
    Van der Valk, Marc
    Burger, David
    Wensing, Annemarie M. J.
    [J]. CLINICAL INFECTIOUS DISEASES, 2024, 79 (01) : 189 - 195
  • [2] Characterization of a case of virological failure after switch to long-acting cabotegravir and rilpivirine
    Mazzitelli, Maria
    Avolio, Antonio
    Carandina, Riccardo
    Parisi, Saverio
    Wensing, Annemarie
    Cattelan, Annamaria
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (08) : 2074 - 2076
  • [3] Long-Acting Injectable Cabotegravir and Rilpivirine in a Pregnant Woman Living With Human Immunodeficiency Virus
    van der Wekken-Pas, Lena
    Weiss, Fabian
    Simon-Zuber, Charlotte
    Sebisch, Rena
    Wiese, Carmen
    van Leeuwen, Elisabeth
    Burger, David
    Colbers, Angela
    [J]. CLINICAL INFECTIOUS DISEASES, 2024,
  • [4] Physiologically-based pharmacokinetic modelling of long-acting injectable cabotegravir and rilpivirine in pregnancy
    Atoyebi, Shakir
    Bunglawala, Fazila
    Cottura, Nicolas
    Granana-Castillo, Sandra
    Montanha, Maiara Camotti
    Olagunju, Adeniyi
    Siccardi, Marco
    Waitt, Catriona
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024,
  • [5] Early adopters of long-acting injectable cabotegravir/rilpivirine: what lessons can we learn?
    Wood, Brian R.
    Kumarasamy, Nagalingeswaran
    [J]. AIDS, 2024, 38 (03) : 425 - 426
  • [6] The optimum implementation of long-acting injectable cabotegravir-rilpivirine in sub-Saharan Africa
    Dawood, Halima
    [J]. LANCET GLOBAL HEALTH, 2021, 9 (05): : E563 - E564
  • [7] Rilpivirine and cabotegravir trough concentrations in people with HIV on long-term treatment with long-acting injectable antiretrovirals
    Cossu, Maria Vittoria
    Cattaneo, Dario
    Moschese, Davide
    Giacomelli, Andrea
    Soloperto, Sara
    D'Avolio, Antonio
    Antinori, Spinello
    Gori, Andrea
    Rizzardini, Giuliano
    Gervasoni, Cristina
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (05) : 1126 - 1132
  • [8] Long-Acting Cabotegravir and Rilpivirine: Innovation, New Challenges, and Opportunities
    Llibre, Josep M.
    Kuritzkes, Daniel A. R.
    [J]. CLINICAL INFECTIOUS DISEASES, 2023, 76 (09) : 1655 - 1657
  • [9] Off-label use of long-acting injectable cabotegravir/rilpivirine in viremic patient living with HIV
    Jorgensen, N. M.
    Larsen, L.
    [J]. HIV MEDICINE, 2023, 24 : 711 - 711
  • [10] Experiences to date with the logistical management of long-acting cabotegravir and rilpivirine
    Johnson, Kamile
    Sawkin, Mark T.
    [J]. DRUGS IN CONTEXT, 2022, 11
12345